Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 1
2001 1
2002 1
2003 1
2004 1
2005 2
2006 3
2007 1
2009 3
2010 7
2011 5
2012 8
2013 5
2014 10
2015 8
2016 18
2017 17
2018 10
2019 15
2020 13
2021 4
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 32358095

110 results
Results by year
Filters applied: . Clear all
Page 1
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R. Molinaro E, et al. J Clin Endocrinol Metab. 2013 Jul;98(7):2693-700. doi: 10.1210/jc.2012-4137. Epub 2013 Apr 26. J Clin Endocrinol Metab. 2013. PMID: 23626005
Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J, Jarząb M, Czarniecka A, Roskosz J, Kukulska A, Handkiewicz-Junak D, Puch Z, Wygoda Z, Paliczka-Cieślik E, Kropińska A, Gubała E, Jurecka-Lubieniecka B, Jarząb B. Krajewska J, et al. Endokrynol Pol. 2016;67(1):2-11. doi: 10.5603/EP.2016.0001. Endokrynol Pol. 2016. PMID: 26884109 Free article.
110 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page